Global pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Galenicum Health, S.L.U. through its subsidiary, Lupin Atlantis Holdings SA (LAHSA), for finished injectable formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.

Under the terms of the agreement, Galenicum will be responsible for the development, manufacturing, and supply of the product, while Lupin will manage regulatory filings, approvals, and the commercialisation and distribution of semaglutide across 23 markets worldwide. These include Canada, Europe, Southeast Asia, and Latin America. The partnership supports Lupin’s strategy to expand its presence in diabetes and obesity management beyond India.

Fabrice Egros, President – Corporate Development at Lupin, said the collaboration represents a strategic step in strengthening the company’s semaglutide portfolio. He noted that with the global rise in diabetes and obesity, semaglutide has emerged as a key therapy, and the partnership positions Lupin to leverage growth opportunities in the expanding GLP-1 market while improving patient access to high-quality and affordable treatment options.

Semaglutide, a GLP-1 receptor agonist, is used to regulate blood glucose levels and appetite. It is primarily prescribed for adults with type 2 diabetes in combination with diet and exercise and is also indicated for long-term weight management in adults with obesity or overweight conditions.

Joaquim Domingo, Co-founder of Galenicum, said the agreement is central to the company’s strategy to scale global volumes of semaglutide. He added that Galenicum has made significant investments in its GLP-1 development pipeline to address growing global demand and aims to establish leadership in the B2B GLP-1 space by offering partners reliable, scalable, and high-quality solutions.

Headquartered in Mumbai, India, Lupin Limited is a global pharmaceutical company with a presence in more than 100 markets worldwide. Its portfolio spans branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Galenicum Health, headquartered in Barcelona, Spain, is a global pharmaceutical company focused on the development, manufacturing, and commercialisation of generic and value-added generic medicines.